Synthetic thymosin alpha 1 (Tα1) peptide has been approved by the FDA for treatment of malignant melanoma, Hepatitis B and C, and influenza. It is indicated as adjuvant therapy for support of immune systems suppressed by chemotherapy.
Thymosin Beta 4 has been found to support protection and regeneration of damaged tissues, so it is primarily recommended to assist in the healing of acute injury, post-surgically, and for older athletes.
BPC 157 is a synthetic peptide that promotes healing. Healing is encouraged through the up regulation of growth factors and the modulation of nitric oxide synthesis. When used in its injectable form, it supports the healing of injury, especially the healing of tendons and ligaments. When used in the oral form, it has been found to heal the gut mucosa and is in clinical trials as a treatment for Inflammatory Bowel Disease, Crohn’s Disease, and gastric ulcers.
LL-37 is a synthetic peptide which plays an important part in the body’s ability to fight infection; it shows a broad spectrum ability to fight bacteria, viruses, and fungi. It is believed to be effective in disrupting both bacterial and viral membranes and has been studied with promising results in RSV, Influenza A, Candida albicans, HIV-1, and staph epidermidis. It may also be beneficial for antibiotic resistant infections and is being considered closely for this application.